RT Journal Article
SR Electronic
T1 An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.26.22271364
DO 10.1101/2022.02.26.22271364
A1 Estrada, Josue Antonio
A1 Cheng, Chien-Yu
A1 Ku, Shin-Yen
A1 Hu, Hui-Chun
A1 Yeh, Hsiu-Wen
A1 Lin, Yi-Chun
A1 Chen, Cheng-Pin
A1 Cheng, Shu-Hsing
A1 Lin, I-Feng
YR 2022
UL http://medrxiv.org/content/early/2022/03/01/2022.02.26.22271364.abstract
AB Background Rapid development and deployment of vaccine is crucial to control the continuously evolving COVID-19 pandemic. Placebo-controlled phase 3 efficacy trial is still standard for authorizing vaccines in majority of the world. However, due to lack of cases or participants in parts of the world, this has not always been feasible. An alternative to efficacy trial is immunobridging, in which the immune response or correlates of protection of a vaccine candidate is compared against an approved vaccine. Here we describe a case study where our candidate vaccine, MVC-COV1901, has been granted for emergency use authorization (EUA) locally based on the non-inferiority immunobridging process.Methods The per protocol immunogenicity (PPI) subset from the MVC-COV1901 phase 2 trial was used for this study and consisted of 903 subjects who have received two doses of MVC-COV1901 as scheduled in the clinical trial. The comparator set of population consisted of 200 subjects of ≥ 20 years of age who were generally healthy and have received two doses of AstraZeneca ChAdOx nCOV-19 (AZD1222) recruited from Taoyuan General Hospital, Ministry of Health and Welfare.Results MVC-COV1901 was shown to have a geometric mean titer (GMT) ratio lower bound 95% confidence interval (CI) of 3.4 against the comparator vaccine and a seroconversion rate of 95.5% at the 95% CI lower bound, which both exceeded the criteria set by the Taiwan regulatory authority for EUA approval. These results supported the EUA approval of MVC-COV1901 by the Taiwanese regulatory authority in July 2021. Following the consensus of the International Coalition of Medicines Regulatory Authorities (ICMRA), countries from the Access Consortium has recently adopted the use of immunobridging studies as acceptable for authorizing COVID-19 vaccines in lieu of efficacy data.Conclusion The data presented in the study showed that it is reasonably likely that the vaccine efficacy of MVC-COV1901 is similar or superior to that of AZ. Data could be used in support of further vaccine development and regulatory approval.Competing Interest StatementJ.A.G.E. is an employee of Medigen Vaccine Biologics (Taipei, Taiwan) and he has received grants from Taiwan Centres for Disease Control, Ministry of Health and Welfare, during the conduct of the study. All other authors declare no conflict of interest.Clinical TrialNCT04695652Funding StatementThe study was funded by Medigen Vaccine Biologics (study sponsor) and the Taiwan Centres for Disease Control, Ministry of Health and Welfare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol and informed consent form were approved by the Taiwan Food and Drug Administration (FDA) and the ethics committees at the participating sites. The institutional review boards involved were the Chang Gung Medical Foundation, National Taiwan University Hospital, Taipei Veterans General Hospital, Tri-Service General Hospital, Taipei Medical University Hospital, Taipei Municipal Wanfang Hospital, Taoyuan General Hospital Ministry of Health and Welfare, China Medical University Hospital, Changhua Christian Hospital, National Cheng Kung University Hospital, and Kaoshiung Medical University Hospital. The trial was done in accordance with the principles of the Declaration of Helsinki and good clinical practice guidelines.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the study are available upon reasonable request to the authors